Premature Ejaculation Without Dapoxetine: Choosing an SSRI the US Actually Has
A single patient asking specifically for a drug that isn't approved in his own country. The disagreement isn't whether an SSRI will help — it's which one, at what schedule, and how directly to address where he first heard about the option he can't actually get.
Toby R., a 29-year-old software QA tester, has had premature ejaculation for as long as he’s been sexually active, an intravaginal latency he estimates at around thirty seconds — inside the one-minute mark the ISSM definition of lifelong premature ejaculation actually turns on, and lifelong rather than acquired in onset, which is the form the SSRI evidence was built on — something he’d managed without treating for years, and something that has become more pressing now that he’s recently divorced and newly serious with someone new. He came in with a specific request: dapoxetine, a name he found on an online forum where other men described it as fast-acting and taken only before sex rather than daily. What he doesn’t yet know is that the drug he’s asking for was designed and studied specifically for this indication, approved in more than fifty countries — and never approved in the United States, where the FDA has never received an application it found approvable.
What’s actually available to him are the conventional daily SSRIs, developed as antidepressants and found, as a side effect, to delay ejaculation — paroxetine, sertraline, and others, used here entirely off-label. Among them, paroxetine showed the strongest ejaculatory delay in Waldinger and colleagues’ meta-analysis of SSRI treatment for premature ejaculation — on daily dosing, more effective than the rest of the class. But paroxetine also carries the most pronounced discontinuation syndrome of any SSRI, a consequence of its short half-life, which matters for a patient who has already told the room he’d rather not be on a daily psychiatric medication at all if he can help it. On-demand dosing of a standard SSRI has been tried and reported in smaller studies, but unlike dapoxetine’s rapid, purpose-built pharmacokinetics, conventional SSRIs generally take days to weeks to reach the steady state their ejaculatory effect depends on — methodologically limited evidence for genuine single-dose efficacy exists, but it isn’t the same footing dapoxetine itself was studied on.
In the clinic, after the forum question
Start daily paroxetine. Among the conventional SSRIs we can actually prescribe here, Waldinger's meta-analysis puts it ahead of the rest of the class on daily dosing — if we're choosing an off-label agent anyway, I'd rather start with the one most likely to give him the result he's actually looking for.
I'd weigh the discontinuation profile more heavily than that. Paroxetine's short half-life gives it the roughest discontinuation syndrome in the class — dizziness, sensory disturbances, irritability — if he stops or misses doses, which a twenty-nine-year-old managing an on-again relationship schedule plausibly will. Sertraline is somewhat less effective on average, but a drug he actually stays on beats a stronger one he abandons.
Leading with 'strongest evidence' treats effect size as the only variable that matters, when tolerability is what actually determines whether he's still taking anything in three months.
Before we pick between those two, I want to address what he actually asked for. Ordering dapoxetine through an overseas pharmacy isn't something we can endorse — there's no FDA oversight of what's actually in that product, and I'd rather he hear that directly from us than infer it from our silence.
On the daily-versus-on-demand question, I'd take his stated preference seriously even though the on-demand evidence for standard SSRIs is weaker — this is a new relationship, not a chronic condition he's resigned to medicating indefinitely, and that context is worth something.
Agreed: start daily sertraline, with explicit counsel against sourcing dapoxetine through unregulated overseas channels; paroxetine held in reserve if sertraline’s effect proves inadequate, with its harder discontinuation profile discussed in advance rather than discovered later.
Not agreed: whether on-demand dosing of a standard SSRI should have been tried before committing to daily use, given his stated preference. The sexual medicine specialist felt the weaker on-demand evidence wasn’t worth delaying effective treatment; the primary care physician thought patient preference deserved more weight when daily-versus-on-demand evidence for these agents isn’t overwhelming in either direction.